Howard Doss
Chief Financial Officer
Replay available
TRxADE HEALTH, Inc. (NASDAQ: MEDS) Q4 2021 earnings conference call, held 2022-03-28. Replay captured from the company's public earnings webcast.

Chief Financial Officer
Founder, Chairman and Chief Executive Officer
Analyst, Maxim Group
Analyst, Taglich Brothers
Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Trixaid Health's fourth quarter and annual 2021 earnings conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be opened for questions. The earnings press release accompanying this conference call was issued at the close of the market today. The annual report, which includes additional information regarding the company's results of operations for the year ended December 31st, 2021, was filed with the SEC earlier today. On our call today is Trixade Health's founder, chairman, and chief executive officer, Shurin Adjarapu, and Howard Doss, its chief financial officer. The replay of this call and webcast will be available for the next 30 days. on the company's website under the NASDAQ MEDS link. The company's website also includes more supporting industry information. At this time, I'd like to turn the call over to Howard Doss, the company's Chief Financial Officer. Howard, the floor is yours. Thank you, Operator, and thank you for joining us today. I'd like to welcome you to our fourth quarter and annual 2021 Financial Results Conference Call. Our press release announcing our 2021 fourth quarter and annual financial results was issued after the close of market today and is posted on our website. We have also furnished such press release to the SEC on Form 8K. Finally, we have published a copy of the presentation that accompanies this call and webcast on our website and furnished such press release and presentation to the SEC on Form 8K. Statements made on this call and webcast include forward-looking statements. These statements include but are not limited to our outlook for the company and statements that estimat...